HER2 Support Group Forums - View Single Post

Lolly · 04-06-2006, 11:41 AM

A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer

http://www.clinicaltrials.gov/ct/show/NCT00179296

“In this study a drug called Tarceva (OSI- 774) will be given in combination with the standard treatment of letrozole for advanced metastatic breast cancers which are sensitive to hormonal treatment…
Primary Outcomes: To determine the rate of clinical benefit (CR + PR + SD) in patients with hormone-dependent metastatic breast cancer treated with the combination of the aromatase inhibitor letrozole plus the EGFR/HER2 inhibitor OSI-774 (‘Tarceva’)..."

04-06-2006, 11:41 AM	#1
Lolly Senior Member Join Date: Aug 2001 Location: Oregon Posts: 1,756	Phase II Trial of Letrozole plus Tarceva A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer http://www.clinicaltrials.gov/ct/show/NCT00179296 “In this study a drug called Tarceva (OSI- 774) will be given in combination with the standard treatment of letrozole for advanced metastatic breast cancers which are sensitive to hormonal treatment… Primary Outcomes: To determine the rate of clinical benefit (CR + PR + SD) in patients with hormone-dependent metastatic breast cancer treated with the combination of the aromatase inhibitor letrozole plus the EGFR/HER2 inhibitor OSI-774 (‘Tarceva’)..."